Signaling Pathways in Tumour Immunity Analysis Service

Under normal circumstances, the immune system can recognise and remove tumour cells from the tumour microenvironment. However, in turn, in order to survive and grow, tumour cells are able to employ different strategies to keep the immune system of the living organism suppressed and unable to recognise and kill tumour cells properly. Thus, ultimately surviving the various stages of the anti-tumour immune response is achieved. The above characteristics of tumour cells are known as immune escape. The normal process of clearance of cancer cells by the immune system of a living organism involves the following seven steps.

Abnormalities in any of these steps can lead to failure of tumour cell clearance and immune escape. Different tumours can inhibit the effective recognition and killing of tumour cells by the immune system through abnormalities in the different steps above, thereby creating immune tolerance and even promoting tumour development and progression.

Fig.1 Metabolic competition between tumour cells and immune cells and tumour metabolite-mediated regulation of immune cells. (Mengtian Wan.; et al, 2021)

Tumour immunotherapy is a therapeutic approach to control and eliminate tumours by restarting and maintaining the tumour-immune cycle and restoring the body's normal anti-tumour immune response. It includes monoclonal antibody-based immune checkpoint inhibitors, therapeutic antibodies, cancer vaccines, cellular therapies and small molecule inhibitors.

Surface plasmon resonance (SPR) for signalling pathways in tumor immunity analysis service

Despite decades of research into the immune system, it has only recently become a target for oncology drug treatments, with researchers attempting to fight cancer by enhancing the interaction between the immune system and the cancer. While this revolutionary anti-cancer strategy has brought hope to many patients, there are still many difficulties to overcome before it can be safe and effective for all cancer patients. One of these obstacles is tumour immunity, but it presents both a challenge and an opportunity. Mechanistic studies of the signalling pathways associated with tumour immunity at the molecular level will involve analysis of molecular interactions, which is important fundamental research. Based on the SPR platform, we can provide high-throughput molecular interaction analysis services to help you discover and study the mechanistic studies of tumour immunity-related signalling pathways and advance the oncology drug development process.

Fig.2 BIAchip™ in the process of tumor immunity analysis service

As shown above, there are still some new directions in tumour immune-related mechanism research, such as the study of regulatory immune checkpoint signalling pathways in the tumour microenvironment, CAR signalling pathways and T-cell receptor-related signalling pathways. If your project has a need in these areas, please consider our high-throughput SPR technology platform.

In addition to high throughput, SPR technology has the advantage of high sensitivity and accuracy compared to traditional and other molecular interoperability platforms. In general, it is rare to have the advantages of both high throughput and high accuracy. But our high sensitivity SPR technology platform has low detection lines and low systematic errors. Last but not least, you have often struggled to find the right service, but when you choose our SPR technology platforms, you get a bespoke service. Thanks to the scalability and flexibility of our technology platform, you can give us your ideas and the Creative Proteomics experts will do their best to meet your requirements and provide you with your own customised chip.

Choosing SPR services of Creative Proteomics, you will greatly save time and money costs owing to high-throughput intermolecular interaction detection. All services are available on a 24/7/365 basis. If you have any questions or suggestions about SPR, please feel free to contact us right now.

For research use only. Not intended for any clinical use.